 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
|
|
|||||||||||||
|
October 3, 2000 Company Press Release Galileo Laboratories Expands Senior Management Team, Adding Nutritional Discovery and Clinical DevelopmentGalileo Names Robert A. Lunbeck, Jr. as Chief Financial Officer, Stephen D. Phinney, M.D., Ph.D., as Vice President Clinical Nutrition, and Sekhar S. Boddupalli, Ph.D., as Vice President Nutrition DiscoverySanta Clara, CA, October 03, 2000 – Galileo Laboratories, Inc. has expanded its senior management team as the company advances its Nutritional Discovery and Development programs. This effort will operate alongside Galileo’s Pharmaceutical programs. Galileo has appointed Robert A. Lunbeck, Jr. as Chief Financial Officer. In this position, Mr. Lunbeck is responsible for directing Galileo’s finance activities, investor relations, and planning for the company’s anticipated high growth. Mr. Lunbeck joins Galileo from Chase H&Q, a leading investment bank, where he spent four years as Senior Healthcare Analyst. Previously, Mr. Lunbeck served as Analyst specializing in healthcare at RCM Capital Management, a San Francisco based institutional money manager, and as Vice President, emphasizing biomedical investing, at Security Pacific Venture Capital. Mr. Lunbeck holds an MBA from Stanford University and an A.B. in Economics, Phi Beta Kappa, from Harvard College, and is a Chartered Financial Analyst. Stephen D. Phinney, M.D., Ph.D., joins Galileo as Vice President Clinical Nutrition. Dr. Phinney develops and manages clinical trials for Galileo’s Nutrition programs. Dr. Phinney brings 20 years of design and clinical trials experience in both academic and industry settings. Over 55 of his peer-reviewed publications have appeared in both clinical nutrition and biochemical journals. “Dr. Phinney’s credentials, expertise, and track record will allow Galileo to efficiently conduct state-of-the-art clinical studies incorporating genomics and wireless applications. This competency will greatly advance the development of personalized, bioactive consumer nutrition products that are evidence-based and exceed current regulatory standards," said Guy Miller, M.D., Ph.D., Chief Executive Officer of Galileo. Dr. Phinney holds an M.D. from Stanford University Medical School and a Ph.D. from MIT in Nutritional Biochemistry. He completed a Clinical Nutrition fellowship at Harvard Medical School, and subsequently held clinical faculty appointments at MIT, University of Vermont College of Medicine, University of Minnesota, and as Professor at the University of California at Davis. Also joining the Galileo senior management team as Vice President Nutrition Discovery is Sekhar Boddupalli, Ph.D. Dr. Boddupalli comes from Monsanto Company where he was Director, Human Nutrition. After completing his training in biochemistry at the Indian Institute of Science in Bangalore, Dr. Boddupalli held faculty appointments at the University of Texas, Southwestern Medical Center, Dallas. About Galileo LaboratoriesGalileo Laboratories discovers and develops proprietary nutritional and pharmaceutical products to address such major chronic conditions as cardiovascular disease and diabetes through mitigating metabolic and oxidative stress. Galileo deploys state-of-the-art pharmaceutical and biotechnology tools to screen and develop bioactive compounds for use as functional foods, complementary medicines, and pharmaceuticals. The company possesses proprietary cell-based technology that models the human metabolism, allowing for rapid screening and isolation of therapeutically beneficial compounds, dramatically speeding time-to-market. Galileo clinical studies provide credible evidence of safety and efficacy. Galileo has strategic product development agreements with leading companies in biotechnology, pharmaceuticals and consumer products. This spring, Nutraceuticals World named Galileo, along with McNeil/J&J, General Mills and Quaker Oats, as one of the industry’s top 10 innovators. ContactPeter
Leighton, Vice President Marketing
Buy acetanilide
Buy Acetanilide
4.5-5 stars based on
435 reviews
Cheapest generic viagra australia generic viagra australia cheapest generic viagra australia cheap How to acetanhydrid kaufen compare prices buy lindberg acetanium with a drug shop? Compare prices with other online drug stores. Add this to comparison charts and reviews! Compare prices with private drugstores. Add this drug to comparison charts and reviews! Compare prices with online pharmacies. Add this drug to comparison charts and reviews! Important Information: This medication is available only in generic dosage forms and does not Venlafaxine hcl er 37.5 mg for hot flashes contain sildenafil. Use the information displayed on this page to help make your decision. This information is an approximation. It based on the best available evidence, but this information should not be used for the treatment or advice of any individual patient. Before starting new supplement, you should consult your healthcare practitioner.
Acetan 40mg $53.35 - $1.78 Per pill
buy lindberg acetanium buy acetanilide acetanilide buy acetanhydrid kaufen buy lindberg acetanium lindberg acetanium kaufen canada pharmacy prescription drug store acetanilide buy acetanilid kaufen buy lindberg acetanium canada drug store pharmacy acetanilide buy Ciprofloxacin dose in child patients, including pregnant women, children, and adults (eTable-5 in the Supplement). Patients should be followed to detect signs of toxicity, which include somnolence, nausea, vomiting, and headache. For patients receiving ceftriaxone in a dose of ≥40 mg/kg body weight/day or a dosage of ≥20 mg/kg daily for ≥3 months (≥4 times the maximum recommended dose) for treatment of MRSA, patients should undergo an additional clinical trial of ceftriaxone to determine an acceptable daily dose if not determined by the FDA (FDA, 2014b). Special Considerations Patients Receiving Metronidazole Metronidazole should not be used alone or in combination with other antibiotics to treat MRSA infections unless the indication specifically requires this combination, or the benefits of combination outweigh risks the medications (Table 8; CDC, 2016). Patients in Respiratory-Related Conditions (eTable-4) In cases where an infection is suspected or where an individual has a history of respiratory disease, antimicrobial exposure should be restricted. If an appropriate alternative antibiotic or therapy is needed for a patient with suspected or active respiratory system infection, the antimicrobial should be discontinued unless it is determined that not required because of the patient's illness or medical conditions. Patients with Respiratory Syndrome (eTable-5) Patients with a history of suspected or active respiratory syndrome requiring antimicrobial therapy (such as pneumonia, pneumonia with or without pleural effusion, bronchitis, acute exacerbations of asthma, or asthma-related pulmonary function tests within the previous 2 weeks) may consider a reduction in total daily dose of any antimicrobial used with such an episode. For patients who need antimicrobial therapy, this should be considered only in patients whose underlying illnesses are stable on normal therapy (eTable-5). Special Consideration Considerations for the Elderly Elderly patients may have compromised immune systems. As a result, antimicrobial therapy should be administered only in patients whose condition warrants antimicrobial therapy. Elderly patients are more likely to have chronic liver disorders that decrease their effectiveness of antimicrobial therapy (CDC, 2016). Patients aged 65 and older who receive antimicrobial treatment should the usual adult dose (eTable-5). In addition, elderly, debilitated patients receiving antibacterial therapy should be observed closely and receive a reduction of the total daily dose if possible. For elderly patients with compromised renal function, the dose reduction may be appropriate. For patients receiving metronidazole, this may be as high 0.1 mg/kg if the clinical significance Divalproex generic price of their illness or clinical situation is uncertain; otherwise, a reduced dose should be administered (eTable-5, also see FDA Guidance for Antimicrobial-Use in Pregnant Women and Children, available at http://www.fda.gov/cder/Drugs/default.htm, on the date of this guideline) (eTable-5). For patients receiving ceftriaxone treatment a suspected or active bacterial respiratory infection, the total daily dose of ceftriaxone may be reduced at the discretion of treating physician for patients receiving any antimicrobial (eTable-4). Decreases in total daily dose or dosage intervals should be made cautiously for patients on antimicrobial-containing therapy or for patients with liver disease and whose renal function is compromised or for patients under the age of 65. For those patients who have a history of pulmonary disease and respiratory conditions that may impact susceptibility to antimicrobial medications, the appropriate therapeutic dosage regimen can be altered as indicated. This includes: (1) reducing the total daily dose of medication; (2) reducing the total dose every 6 weeks to a goal dosage of 250–800 mg/day; and (3) reducing the time between doses from 1 week to 3 weeks (eTable-4) (CDC, 2016). For patients receiving antimicrobial treatment as part of a respiratory-related bacterial infections management and care plan, treatment adjustments (eTable-4) should be made in accordance with the guidelines of an ACAM task force (ACAM, 2011). Special Considerations for Infants, Children, and Pregnant Women Infants, children, and pregnant women may have altered susceptibility to antimicrobial agents. For these patients, appropriate adjustment of the daily dose and/or dosage intervals of antimicrobial agents may be necessary (eTable-5). A reduced dose should be administered in such instances. If a reduction or interruption (or combination with antimicrobial treatment) is necessary, clinicians should discuss this with the treating physician to assess whether the patient will need antimicrobial drug regimens that are different than those they started on. A reduction or interruption in the total daily dose of any antimicrobial may need to be made if the total daily.
|
||||||||||||
